BG Medicine Inc (BGMD) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
880 WINTER STREET WALTHAM, MA 02451 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | 12/31/2014 Q4 | 9/30/2014 Q3 | 6/30/2014 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,642 | 178 | 1,612 | 4,123 | 6,313 | 9,538 | |||
| Cash and cash equivalent | 2,642 | 178 | 1,612 | 4,123 | 6,313 | 9,538 | |||
| Receivables | 152 | 255 | 132 | 174 | 254 | 353 | |||
| Inventory, net of allowances, customer advances and progress billings | 223 | 300 | 280 | 400 | 358 | 554 | |||
| Inventory | 223 | 300 | 280 | 400 | 358 | 554 | |||
| Prepaid expense | 250 | ||||||||
| Other undisclosed current assets | 139 | 415 | 249 | (96) | 236 | 352 | |||
| Total current assets: | 3,156 | 1,148 | 2,273 | 4,851 | 7,161 | 10,797 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 14 | 18 | 103 | 117 | 135 | 154 | |||
| Intangible assets, net (including goodwill) | 92 | 106 | 120 | 135 | 149 | 163 | |||
| Intangible assets, net (excluding goodwill) | 92 | 106 | 120 | 135 | 149 | 163 | |||
| Investments and other noncurrent assets | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 126 | ||
| Other undisclosed noncurrent assets | 94 | 94 | 94 | 126 | 126 | ||||
| Total noncurrent assets: | 200 | 218 | 317 | 378 | 410 | 443 | |||
| TOTAL ASSETS: | 3,356 | 1,366 | 2,590 | 5,229 | 7,571 | 11,240 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,894 | 1,883 | 1,194 | 1,972 | 1,677 | 1,936 | |||
| Interest and dividends payable | 222 | ||||||||
| Employee-related liabilities | 149 | ||||||||
| Accounts payable | 1,332 | 610 | 579 | 695 | 425 | 1,012 | |||
| Accrued liabilities | 562 | 1,273 | 615 | 906 | 1,252 | 924 | |||
| Debt | 745 | 1,856 | 2,960 | 4,059 | 4,406 | ||||
| Other liabilities | 48 | 80 | 20 | 18 | 42 | 69 | |||
| Deferred revenue and credits | |||||||||
| Other undisclosed current liabilities | 929 | (371) | |||||||
| Total current liabilities: | 1,942 | 3,637 | 3,070 | 4,579 | 5,778 | 6,411 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 745 | ||||||||
| Long-term debt, excluding current maturities | 745 | ||||||||
| Liabilities, other than long-term debt | 94 | 104 | 86 | 93 | 97 | 102 | |||
| Deferred revenue and credits | |||||||||
| Other liabilities | 94 | 104 | 86 | 93 | 97 | 102 | |||
| Total noncurrent liabilities: | 94 | 104 | 86 | 93 | 97 | 847 | |||
| Total liabilities: | 2,036 | 3,741 | 3,156 | 4,672 | 5,875 | 7,258 | |||
| Temporary equity, including noncontrolling interest | 2,594 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,274) | (2,375) | (566) | 557 | 1,696 | 3,982 | |||
| Common stock | 11 | 9 | 34 | 34 | 34 | 34 | |||
| Additional paid in capital | 165,618 | 161,995 | 161,749 | 161,525 | 161,343 | 161,234 | |||
| Accumulated deficit | (165,403) | (164,379) | (162,349) | (161,002) | (159,681) | (157,286) | |||
| Other undisclosed equity, attributable to parent | (1,500) | ||||||||
| Total equity: | (1,274) | (2,375) | (566) | 557 | 1,696 | 3,982 | |||
| TOTAL LIABILITIES AND EQUITY: | 3,356 | 1,366 | 2,590 | 5,229 | 7,571 | 11,240 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | 12/31/2014 Q4 | 9/30/2014 Q3 | 6/30/2014 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 334 | 505 | 437 | 554 | 695 | 799 | ||
| Cost of revenue (Cost of Product and Service Sold) | (103) | (172) | (149) | (192) | (234) | (281) | ||
| Gross profit: | 231 | 333 | 288 | 362 | 461 | 518 | ||
| Operating expenses | (1,257) | (1,929) | (1,594) | (1,630) | (3,098) | (2,489) | ||
| Other undisclosed operating income (loss) | 151 | 50 | 57 | 404 | ||||
| Operating loss: | (1,026) | (1,445) | (1,256) | (1,211) | (2,233) | (1,971) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 7 | (521) | 22 | 1 | 1 | |||
| Interest and debt expense | (4) | (63) | (92) | (131) | (165) | (199) | ||
| Loss from continuing operations: | (1,023) | (2,029) | (1,348) | (1,320) | (2,397) | (2,169) | ||
| Loss before gain (loss) on sale of properties: | (1,023) | (2,029) | (1,348) | (1,320) | (2,397) | (2,169) | ||
| Net loss attributable to parent: | (1,023) | (2,029) | (1,348) | (1,320) | (2,397) | (2,169) | ||
| Preferred stock dividends and other adjustments | (1,604) | |||||||
| Net loss available to common stockholders, diluted: | (2,627) | (2,029) | (1,348) | (1,320) | (2,397) | (2,169) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2015 Q4 | 9/30/2015 Q3 | 6/30/2015 Q2 | 3/31/2015 Q1 | 12/31/2014 Q4 | 9/30/2014 Q3 | 6/30/2014 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,023) | (2,029) | (1,348) | (1,320) | (2,397) | (2,169) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,023) | (2,029) | (1,348) | (1,320) | (2,397) | (2,169) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.